e-1r

E1R is a positive sigma-1 receptor (Sig1R PAM) allosteric modulator. It has a cognition-enhancing activity.

(2R,3S)-E1R (Compound 2c) is an enantiomer of E1R. (2R,3R)-E1R is a sigma-1 receptor positive allosteric modulator for treating cognition and memory disorders.

(2S,3S)-E1R (Compound 2d) is an enantiomer of (2R,3R)-E1R, a sigma-1 receptor positive allosteric modulator for the treatment of cognition/memory disorders.

(2R,3R)-E1R is an enantiomer of E1R. (2R,3R)-E1R is a sigma-1 receptor positive allosteric modulator for the treatment of cognition/memory disorders.

(Rac)-E1R is the racemate of E1R. (Rac)-E1R is a sigma-1 receptor positive allosteric (Sig1R PAM) modulator of for the treatment of cognition/memory disorders.

Exendin-4 (Exenatide) is a glucagon-like peptide-1 receptor (GLP-1) agonist (IC50: 3.22 nM). Exenatide is a 39 amino acid peptide. Compared to GLP-1, exenatide has a longer half-life of 2.4 hours.

D-F07 belongs to fluorescent dye-class tricyclic chromone compounds and is an IRE1 inhibitor (prodrug form containing an aldehyde-masked group) with cell permeability. This compound induces tumor cell apoptosis through inhibition of the IRE1/XBP1 pathway, exhibiting significant antitumor activity, and is suitable for related mechanism research and antitumor drug development.

B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.

Telmisartan (BIBR 277) is an Angiotensin 2 Receptor Blocker. The mechanism of action of telmisartan is as an Angiotensin 2 Receptor Antagonist.

Azilsartan Medoxomil (TAK-491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

L162441 is an antagonist of Angiotensin type 1 receptor.

MKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29 μM in human vitro). MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibit prostate cancer (PCa) tumor growth.

4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM.

Ape1/Ref-1 redox-IN-1 (Compound 52) is an inhibitor of the Ape1/Ref-1 redox process. It is applicable for cancer research.

angiotensin AT1 receptor antagonist

LY301875 is an antagonist of nonpeptide angiotensin receptor.

TRV055 acetate is a ligand of angiotensin II type 1 receptor and stimulates cellular Gq-mediated signaling.

4μ8C (IRE1 Inhibitor III) is a highly selective and potent inhibitor of IRE1α ribonuclease (RNase) activity (IC₅₀ ≈ 6–10 μM). By forming a covalent bond with the RNase active site of IRE1α, 4μ8C specifically inhibits its ribonuclease activity, thereby blocking the splicing of XBP1 mRNA. 4μ8C can be used in research on endoplasmic reticulum stress, the unfolded protein response, immune regulation, and tumor and metabolic diseases.

Survodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptors (GLP Receptor) that reduces body weight in HbA1c16 diabetes.

Avexitide acetate (exendin 9-39) is a potent glucagon-like peptide 1 receptor (GLP-1R) antagonist for the study of post-obesity hypoglycemia.

TRV120027 TFA is a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R) and engages ß-arrestins while blocking G-protein signaling.

4E1rcat 17d features a core structure of (E)-3-(2-furanmethylmethylene)-2-pyrrolidone, and its analog 4E1rcat blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 1 has a core structure of (E)-3-(2-furanmethylmethylene)-2-pyrrolidone, and its analog 4E1rcat blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1RCat analogue 2 has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidinone, and its analog 4E1RCat blocks the interactions between ATG5–ATG16L1 and ATG5–TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.